BCLSI
IPSC icon

Bain Capital Life Sciences Investors’s Century Therapeutics IPSC Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,538,609
Closed -$1.76M – 21
2025
Q3 		$1.76M Sell
3,538,609
-1,871,752
-35% -$1.01M 0.12% 20
2025
Q2 		$3.02M Hold
5,410,361
– – 0.38% 18
2025
Q1 		$2.58M Hold
5,410,361
– – 0.38% 20
2024
Q4 		$5.46M Hold
5,410,361
– – 0.64% 19
2024
Q3 		$9.25M Hold
5,410,361
– – 0.96% 14
2024
Q2 		$13.8M Buy
+5,410,361
New +$17.1M 1.51% 13

Other funds holding IPSC

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bain Capital Life Sciences Investors's IPSC Position: Q4 2025 in Review

Bain Capital Life Sciences Investors sold out of Century Therapeutics (IPSC) in Q4 2025, closing a stake of 3,538,609 shares — an estimated $1.76M sold.

Bain Capital Life Sciences Investors first reported a position in IPSC in Q2 2024 and held it in 6 quarters. The position peaked at $13.8M in Q2 2024. 47 funds tracked by Wall St. Rank hold IPSC as of Q4 2025.

  • Bain Capital Life Sciences Investors reported no remaining Century Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Bain Capital Life Sciences Investors sold 3,538,609 Century Therapeutics shares in Q4 2025, an estimated $1.76M.
  • Bain Capital Life Sciences Investors first reported a position in Century Therapeutics in Q2 2024 and held it in 6 quarters.
  • Bain Capital Life Sciences Investors's Century Therapeutics position peaked at $13.8M in Q2 2024.
  • 47 funds tracked by Wall St. Rank held Century Therapeutics as of Q4 2025.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2025, filed 17 Feb 2026.